March 13, 2009

Apr 9, 2011   //   by Peter Rogan   //   News  //  No Comments

Through its Pre-commercialization Business Development Fund (PBDF) program, the Ontario Genomics Institute (OGI) has invested in Cytognomix, to enable development of novel cytogenetic DNA probes that pinpoint genomic anomalies at higher resolution than existing products. Read full story. Article in GenomeWeb

More about Peter Rogan
Written by: Peter Rogan on April 9, 2011.
Last revised by: Peter Rogan on May 24, 2011.

Comments are closed.